Soleno Therapeutics Inc
6XC
Company Profile
Business description
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
Contact
100 Marine Parkway
Suite 400
Redwood CityCA94065
USAT: +1 650 213-8444
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
152
Stocks News & Analysis
stocks
Is AUB an opportunity after shares plunge 17%?
After a takeover bid was withdrawn shares dropped to below the pre-bid price.
stocks
Attractive ASX listed income opportunity
A high forward distribution yield may entice income investors.
stocks
Have the 3 biggest losers of the ASX 200 fallen too far?
Finding value in some of the ASX’s worst recent performers.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,877.50 | 8.50 | -0.10% |
| CAC 40 | 8,113.54 | 16.54 | 0.20% |
| DAX 40 | 23,699.47 | 110.03 | 0.47% |
| Dow JONES (US) | 47,289.33 | 427.09 | -0.90% |
| FTSE 100 | 9,724.30 | 21.77 | 0.22% |
| HKSE | 26,095.05 | 61.79 | 0.24% |
| NASDAQ | 23,275.92 | 89.76 | -0.38% |
| Nikkei 225 | 49,303.45 | 0.17 | 0.00% |
| NZX 50 Index | 13,502.77 | 54.28 | 0.40% |
| S&P 500 | 6,812.63 | 36.46 | -0.53% |
| S&P/ASX 200 | 8,579.70 | 7.60 | -0.09% |
| SSE Composite Index | 3,897.71 | 16.29 | -0.42% |